Literature DB >> 14730596

Assessment of patients with psoriatic arthritis: a review of currently available measures.

Dafna D Gladman1, Philip Helliwell, Philip J Mease, Peter Nash, Christopher Ritchlin, William Taylor.   

Abstract

Entities:  

Mesh：

Year:  2004        PMID： 14730596     DOI： 10.1002/art.11417

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN： 0004-3591


× No keyword cloud information.
  35 in total

Review 1.  Management of psoriatic arthritis: the therapeutic interface between rheumatology and dermatology.

Authors:  Philip Mease
Journal:  Curr Rheumatol Rep       Date:  2006-10       Impact factor: 4.592

Review 2.  OMERACT 7 psoriatic arthritis workshop: synopsis.

Authors:  D D Gladman; V Strand; P J Mease; C Antoni; P Nash; A Kavanaugh
Journal:  Ann Rheum Dis       Date:  2005-03       Impact factor: 19.103

3.  Comparison of different outcome measures for psoriatic arthritis in patients treated with infliximab or placebo.

Authors:  B Vander Cruyssen; F De Keyser; E Kruithof; H Mielants; F Van den Bosch
Journal:  Ann Rheum Dis       Date:  2007-01       Impact factor: 19.103

4.  Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006.

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; P Emery; E C Keystone; M H Schiff; P L C M van Riel; M E Weinblatt; M H Weisman
Journal:  Ann Rheum Dis       Date:  2006-11       Impact factor: 19.103

5.  Infliximab in refractory psoriatic arthritis with severe psoriasis: a 2-year experience.

Authors:  Paraskevi V Voulgari; Aliki I Venetsanopoulou; Efstratios K Epagelis; Yannis Alamanos; Ioanna Takalou; Alexandros A Drosos
Journal:  Ann Rheum Dis       Date:  2006-10-26       Impact factor: 19.103

6.  The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year.

Authors:  A Kavanaugh; C E Antoni; D Gladman; S Wassenberg; B Zhou; A Beutler; G Keenan; G Burmester; D E Furst; M H Weisman; J R Kalden; J Smolen; D van der Heijde
Journal:  Ann Rheum Dis       Date:  2006-01-26       Impact factor: 19.103

Review 7.  Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007.

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; J Sieper; P Emery; E C Keystone; M H Schiff; P Mease; P L C M van Riel; R Fleischmann; M H Weisman; M E Weinblatt
Journal:  Ann Rheum Dis       Date:  2007-11       Impact factor: 19.103

Review 8.  [Psoriatic arthritis. Treatment outcome parameters].

Authors:  E Märker-Hermann; F Behrens
Journal:  Z Rheumatol       Date:  2009-02       Impact factor: 1.372

Review 9.  Treatment recommendations for psoriatic arthritis.

Authors:  C T Ritchlin; A Kavanaugh; D D Gladman; P J Mease; P Helliwell; W-H Boehncke; K de Vlam; D Fiorentino; O Fitzgerald; A B Gottlieb; N J McHugh; P Nash; A A Qureshi; E R Soriano; W J Taylor
Journal:  Ann Rheum Dis       Date:  2008-10-24       Impact factor: 19.103

10.  Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions.

Authors:  F Van den Bosch; B Manger; P Goupille; N McHugh; E Rødevand; P Holck; R F van Vollenhoven; M Leirisalo-Repo; O Fitzgerald; M Kron; M Frank; S Kary; H Kupper
Journal:  Ann Rheum Dis       Date:  2009-10-07       Impact factor: 19.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.